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A
dvances in CT technology have expanded our ability to
noninvasively image the coronary arteries. The use of CT
scanning has increased significantly in the last few years.
Efforts to synthesize and interpret clinical trial data to best
inform the rational clinical use of coronary computed tomo-
graphic angiography (CCTA) need to keep pace with the
increased utilization of this promising technology.
In this issue of JGIM, Ollendorf et al. present a scholarly and
thoughtful systematic review of the literature of CCTA’s
diagnostic accuracy and the impact of CCTA on clinical
decision-making and outcomes.
1 They find that the pooled
mean sensitivity is 98% and specificity is 85% for the 42
diagnostic studies of CCTA current to February 2010. However,
these findings must be viewed in light of significant limitations.
These limitations lie not in the quality of this excellent analysis,
but in the meager and narrow data that supports our current
use of cardiac CTA for diagnosis of patients with suspected
CAD. The authors find that “spectrum bias” (which the authors
define as “the systematic variation of diagnostic test perfor-
mance across patient subgroups coupled with the failure to
present all such subgroups in a study”) was present in the
majority of CCTA studies. The existing data for cardiac CT
derives almost entirely from patients already scheduled for
invasive coronary angiography, where pretest probability is
quite high. Indeed, even though most of the studies excluded
patients with known CAD or a history of revascularization, the
mean prevalence of CAD in all CCTA studies was an
astonishingly high 59.3%. By comparison, in a recent report
involving the National Cardiovascular Data Registry, only
37.6% of patients referred for elective coronary angiography
exhibited obstructive CAD.
2 Clearly, the population of patients
studied in the CCTA trials does not resemble the average
American referred for coronary angiography. Furthermore,
there is an even more striking disconnect between the
populations included in these diagnostic accuracy trials of
CCTA and the low to intermediate risk pretest probability of
CAD patients—patients that published clinical guidelines
consider the appropriate population for the use of CCTA for
CAD detection.
3 As Bayes' theorem tells us, the accuracy of
diagnostic tests decreases significantly in a population with a
lower pretest probability of disease.
4 This difference in the
populations where CCTA is studied and the populations in
which CCTA is considered appropriate for use means that it is
highly likely that the diagnostic accuracy of CCTA in clinical
use has been overestimated. Unfortunately, the low pretest
probability population (the population in which cardiac CTA is
commonly used in actual clinical practice) is precisely the
population where clinical trial data is sorely lacking. Conclu-
sions from systematic reviews, even high quality ones such as
that of Ollendorf et al., necessarily are limited due to the
restrictions in the data that comprises them.
Although it is common for tests or therapies to be studied
first in high risk populations, it is essential that they also be
evaluated in the much larger lower risk population in which
they will be used most commonly prior to widespread use of the
new technology. New tests, such as cardiac CT, which has not
been studied in a low probability population, should be used
only in the context of a clinical trial until appropriate data can
be collected and analyzed. A recent case report of a 52-year-old
woman with hypertension, who had sharp nonexertional chest
pain reproducible on palpation, illustrates the importance of a
clear understanding of risks and benefits for cardiac CT
imaging in a low pretest probability population. This unfortu-
nate woman’s doctor ordered a cardiac CT, simply to “reassure“
her—a decision that led to disastrous consequences.
5 Our
enthusiasm for tests, especially for mere “reassurance,” should
not displace the substantial reassurance provided simply by
talking to our patients. The temptation to order an imaging test
for patients with a low probability of CAD is due, in part, to a
misconception of the usefulness of a diagnostic test where the
pretest probability of disease is minimal. The fact that many
diagnostic tests are not without their own risks urges even more
wisdom in their use. Although a single case report cannot tell us
the frequency of use of cardiac CT for such low probability
patients, it nevertheless serves as a strong cautionary tale.
There are many factors contributing to the rapidly increased
use of CT imaging related to an overestimation of the benefits of
this technology and an under appreciation of the risks, as well
as the rapid increase in US-based cardiology practices that
own or lease cardiac CTequipment,
1 as noted by Ollendorf. The
systematic review by Ollendorf et al. highlights the limitations
of the current data on diagnostic accuracy, revealing there are
no substantial data from studies of patients with low and
intermediate pretest probability of CAD (the most common use
of cardiac CT currently). The danger of a seemingly harmless
noninvasive test like a CTscan is that it is easy for patients and
physicians to be unaware of the potentially serious negative
consequences of this test. False positives increase as the
prevalence of true disease decreases in the population studied
for any diagnostic test. False positives for a cardiac CTA mean
that additional testing, often invasive coronary angiography
(ICA),willbeperformed,asintheabovecasereport.Inadditionto
false positives, cardiac CT scans can have real and potentially
dangerous consequences from apparent ‘incidentalomas.’ A
recent study found that 40% of research imaging exams on
otherwise healthy people had incidental findings that led to Published online January 29, 2011
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6Inaddition,weknowthat
there are significant radiation risks associated with CT scans,
particularly in young and middle-aged patients whose lifetime
risk for cancer from cumulative CTscans is higher.
7,8
Ollendorf et al. also summarize the limited data for cardiac CT
for clinical decision-making and outcomes. Only two studies
compared CCTA to standard care in a total of 255 patients with
6- to 12-month follow-up. There were no major cardiovascular
events in either group, although the revascularization rate was
muchhigherintheCCTAgroup.Onecannotconcludemuchfrom
thesepreliminarystudiesbesidesthefactthatthesewereverylow
risk patients and that more studies with longer follow-up are
needed. Although this population of low to intermediate risk
emergencydepartmentpatientsis ofgreatestinterest forCCTA,it
currently has little data to support its use.
Wise use of cardiac CT imaging, like any test or therapy,
involves a thoughtful consideration of risks and benefits, and
hopefully a frank discussion of these with the patient. To have a
truly informed discussion, we must have high quality data on
these risks and benefits. Ollendorf et al. do an excellent job on
showing us where we are currently, and how far we have to go.
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